- Home
- DTF vs BEAT Comparison
DTF vs BEAT Comparison
Compare DTF & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTF
- BEAT
- Stock Information
- Founded
- DTF 1991
- BEAT 2015
- Country
- DTF United States
- BEAT United States
- Employees
- DTF N/A
- BEAT N/A
- Industry
- DTF Investment Managers
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- DTF Finance
- BEAT Technology
- Exchange
- DTF Nasdaq
- BEAT Nasdaq
- Market Cap
- DTF 78.9M
- BEAT 66.1M
- IPO Year
- DTF N/A
- BEAT 2021
- Fundamental
- Price
- DTF $11.24
- BEAT $2.83
- Analyst Decision
- DTF
- BEAT Buy
- Analyst Count
- DTF 0
- BEAT 1
- Target Price
- DTF N/A
- BEAT $8.00
- AVG Volume (30 Days)
- DTF 21.1K
- BEAT 101.3K
- Earning Date
- DTF 01-01-0001
- BEAT 11-07-2024
- Dividend Yield
- DTF 3.64%
- BEAT N/A
- EPS Growth
- DTF N/A
- BEAT N/A
- EPS
- DTF 0.44
- BEAT N/A
- Revenue
- DTF N/A
- BEAT N/A
- Revenue This Year
- DTF N/A
- BEAT N/A
- Revenue Next Year
- DTF N/A
- BEAT N/A
- P/E Ratio
- DTF $24.34
- BEAT N/A
- Revenue Growth
- DTF N/A
- BEAT N/A
- 52 Week Low
- DTF $10.29
- BEAT $1.06
- 52 Week High
- DTF $11.19
- BEAT $3.39
- Technical
- Relative Strength Index (RSI)
- DTF 45.87
- BEAT 65.92
- Support Level
- DTF $11.21
- BEAT $2.33
- Resistance Level
- DTF $11.37
- BEAT $2.70
- Average True Range (ATR)
- DTF 0.07
- BEAT 0.23
- MACD
- DTF -0.00
- BEAT 0.02
- Stochastic Oscillator
- DTF 37.97
- BEAT 68.93
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTFTax-Free Income Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax consistent with preservation of capital. The fund seeks to achieve its investment objective by investing in a diversified portfolio of investment-grade tax-exempt obligations.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.